logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Long-lasting insecticidal nets provide protection against malaria for only a single year in Burundi, an African highland setting with marked malaria seasonality

Van Bortel W, Mariën J, Jacobs BKM, Sinzinkayo D, Sinarinzi P,  et al.
2022-12-01 • BMJ Global Health
2022-12-01 • BMJ Global Health
BACKGROUND
Long-lasting insecticidal nets (LLINs) are one of the key interventions in the global fight against malaria. Since 2014, mass distribution campaigns of LLINs aim for unive...
Journal Article
|
Research

AmBisome monotherapy and combination AmBisome - miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: a randomised open label, parallel arm, phase 3 trial

Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
Journal Article
|
Research

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R,  et al.
2016-09-14 • PLOS Neglected Tropical Diseases
2016-09-14 • PLOS Neglected Tropical Diseases
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBis...
Protocol
|
Research Protocol

A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine

Hailu ADE, Diro EGJ, Kolja S, Ritmeijer KKD, Yifru S,  et al.
2018-07-01
2018-07-01
General Objectives
The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected
patients.
Primary Objective:
To evaluate...
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...